HOOKIPA Pharma Inc. (HOOK): Nasdaq/NYSE listing notice — HOOKIPA Pharma receives Nasdaq bid price deficiency notice; has 180 days to regain compliance

HOOKIPA Pharma Inc.

Received Nasdaq letter on Aug 3, 2023 due to closing bid price below $1.00 for 30 consecutive business days.
Non-compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on Global Select Market.
Automatic 180-day cure period until Jan 30, 2024; must have $1.00 closing bid for 10 consecutive days.
If still non-compliant by Jan 30, 2024, may qualify for a second 180-day period if certain requirements met.
Evaluating options including reverse stock split; stock continues trading under "HOOK" with no immediate effect.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

HOOKIPA Pharma Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

PA Pharma Inc. (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of the Company’s common stock was below $1.00 per share for 30 consecutive business days, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The notice from Nasdaq has no immediate effect on the listing of the Company’s common stock, and the common stock will continue to be listed on the Nasdaq Global Select Market under the s

View on SEC.gov

Browse all listing & compliance notices →

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-087830

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.